Workflow
业聚医疗(06929) - 2023 - 中期业绩
06929ORBUSNEICH(06929)2023-08-17 08:30

Revenue Growth - Revenue increased by 18.2% to 81.41millioninthefirsthalfof2023comparedto81.41 million in the first half of 2023 compared to 68.85 million in the same period of 2022[2] - Revenue from external customers increased to 81.41millioninthefirsthalfof2023,upfrom81.41 million in the first half of 2023, up from 68.85 million in the same period in 2022, representing an 18.2% growth[16] - Revenue for the first half of 2023 increased by 18.2% year-over-year to 81.4million,drivenbystrongsalesgrowthinPCIandPTAballoons[32]−Totalrevenueincreasedby81.4 million, driven by strong sales growth in PCI and PTA balloons[32] - Total revenue increased by 12.5 million (18.2%) from 68.9millioninH12022to68.9 million in H1 2022 to 81.4 million in H1 2023, driven by growth in coronary and peripheral balloon products[47] Gross Profit and Margin - Gross profit rose by 22.1% to 58.27million,withgrossmarginimprovingto71.658.27 million, with gross margin improving to 71.6% from 69.3%[2] - Gross profit increased by 22.1% to 58.3 million, with gross margin improving from 69.3% to 71.6% due to higher sales of scoring balloons in Japan and the US[51] Net Profit and Margin - Net profit attributable to owners surged by 213.3% to 25.18million,withnetmarginexpandingto30.925.18 million, with net margin expanding to 30.9% from 11.7%[2] - Adjusted net profit (non-HKFRS measure) grew by 105.6% to 25.37 million, with adjusted net profit margin increasing to 31.2% from 17.9%[2] - Profit attributable to owners of the company increased to 25.18millioninH12023,morethantriplethe25.18 million in H1 2023, more than triple the 8.04 million in H1 2022[25] - Net profit attributable to shareholders surged by 213.3% to 25.2millioninH12023,withanetprofitmarginof30.925.2 million in H1 2023, with a net profit margin of 30.9%, up 19.2 percentage points year-over-year[32] - Net profit attributable to shareholders increased by 213.3% to 25.2 million, driven by higher gross profit, increased bank interest income, and absence of listing expenses[60] Earnings Per Share - Basic earnings per share increased by 118.7% to 3.04 US cents, while diluted EPS rose by 152.5% to 3.03 US cents[2] - Basic earnings per share grew to 3.04 cents in H1 2023, up from 1.39 cents in H1 2022[25] Operating Profit - Operating profit more than doubled to 24.11millionfrom24.11 million from 10.92 million in the prior year period[6] - Core operating profit grew by 52.1% to 20.4million,withacoreoperatingprofitmarginof25.120.4 million, with a core operating profit margin of 25.1%, up 5.6 percentage points year-over-year[33] Finance Income and Costs - Finance income net of costs improved significantly to 4.19 million from a loss of 1.16millionin2022[6]−Thecompanyrecordedanetfinancingincomeof1.16 million in 2022[6] - The company recorded a net financing income of 4.2 million, compared to a net financing cost of 1.2millioninH12022,mainlyduetohigherinterestincomefromfixeddeposits[57]ComprehensiveIncome−Totalcomprehensiveincomeattributabletoownersincreasedto1.2 million in H1 2022, mainly due to higher interest income from fixed deposits[57] Comprehensive Income - Total comprehensive income attributable to owners increased to 23.89 million from 4.20millioninthefirsthalfof2022[7]ForeignExchange−Thecompanyreportedaforeignexchangelossof4.20 million in the first half of 2022[7] Foreign Exchange - The company reported a foreign exchange loss of 1.25 million, compared to a loss of 4.08millioninthesameperiodlastyear[7]−Netforeignexchangelossesdecreasedto4.08 million in the same period last year[7] - Net foreign exchange losses decreased to 0.69 million in H1 2023 from 1.20millioninH12022[19]−Thecompanyrecordedanetforeignexchangelossof1.20 million in H1 2022[19] - The company recorded a net foreign exchange loss of 0.7 million for the six months ended June 30, 2023, down from 1.2millioninthesameperiodof2022[64]AssetsandLiabilities−Totalassetsincreasedto1.2 million in the same period of 2022[64] Assets and Liabilities - Total assets increased to 373,197 thousand as of June 30, 2023, compared to 351,060thousandasofDecember31,2022[8]−Non−currentassetsgrewto351,060 thousand as of December 31, 2022[8] - Non-current assets grew to 38,576 thousand from 36,785thousandoverthesameperiod[8]−Currentassetsroseto36,785 thousand over the same period[8] - Current assets rose to 334,621 thousand from 314,275thousand[8]−Inventoryincreasedto314,275 thousand[8] - Inventory increased to 33,292 thousand from 29,400thousand[8]−Tradereceivablesgrewto29,400 thousand[8] - Trade receivables grew to 36,424 thousand from 32,322thousand[8]−Cashandbankbalancesincreasedto32,322 thousand[8] - Cash and bank balances increased to 239,031 thousand from 229,146thousand[8]−Totalliabilitiesdecreasedto229,146 thousand[8] - Total liabilities decreased to 26,552 thousand from 28,494thousand[9]−Currentliabilitiesreducedto28,494 thousand[9] - Current liabilities reduced to 22,355 thousand from 23,812thousand[9]−Non−currentliabilitiesdecreasedto23,812 thousand[9] - Non-current liabilities decreased to 4,197 thousand from 4,682thousand[9]−Totalcurrentassetsreached4,682 thousand[9] - Total current assets reached 334.6 million as of June 30, 2023, compared to 314.3millionasofDecember31,2022,whiletotalcurrentliabilitiesdecreasedto314.3 million as of December 31, 2022, while total current liabilities decreased to 22.4 million from 23.8million[63]−Netcurrentassetsincreasedby7.523.8 million[63] - Net current assets increased by 7.5% to 312.3 million as of June 30, 2023, compared to 290.5 million as of December 31, 2022[64] R&D Expenses - R&D expenses remained stable at 6.87 million, representing 8.4% of revenue[6] - R&D expenses increased by 2.2% to 6.9million,primarilyduetohigheremployeebenefitsandproductregistrationfees[56]SalesandDistributionExpenses−Salesanddistributionexpensesincreasedby17.26.9 million, primarily due to higher employee benefits and product registration fees[56] Sales and Distribution Expenses - Sales and distribution expenses increased by 17.2% to 19.3 million due to higher sales commissions and increased marketing activities[54] Employee Benefits - Employee benefit expenses rose to 26.39millioninH12023,up8.526.39 million in H1 2023, up 8.5% from 24.33 million in H1 2022[20] - Employee benefits expenses, including director remuneration, amounted to 26.4millionforthesixmonthsendedJune30,2023,upfrom26.4 million for the six months ended June 30, 2023, up from 24.3 million in the same period of 2022[66] Regional Revenue - Revenue from the Asia-Pacific region (excluding Japan and China) grew to 18.92millioninH12023,up14.218.92 million in H1 2023, up 14.2% from 16.57 million in H1 2022[16] - Revenue from China increased to 18.28millioninH12023,a23.418.28 million in H1 2023, a 23.4% rise compared to 14.82 million in H1 2022[16] - Japan revenue grew by 14.4% to 19.6millioninH12023,drivenbystrongsalesoftheScoreflexTRIOscoringballoonseries[34]−Europe,MiddleEast,andAfricarevenueincreasedby14.219.6 million in H1 2023, driven by strong sales of the Scoreflex TRIO scoring balloon series[34] - Europe, Middle East, and Africa revenue increased by 14.2% to 18.9 million, supported by higher adoption of new-generation products like Sapphire 3 and Sapphire NC 24[35] - Asia-Pacific revenue rose by 23.4% to 18.3million,drivenbystrongsalesinSingapore,Malaysia,andincreasedcoronarystentsalesinIndonesiaandVietnam[36]−ChinarevenuereachedRMB91.8million,up8.218.3 million, driven by strong sales in Singapore, Malaysia, and increased coronary stent sales in Indonesia and Vietnam[36] - China revenue reached RMB 91.8 million, up 8.2% year-over-year, but remained flat at 13.3 million due to RMB depreciation against the USD[37] - US market revenue increased by 61.6% YoY to 11.3million,withsalesofscoringballoonsdoublingcomparedtothepreviousyear[39]−RevenuefromtheUSmarketincreasedby11.3 million, with sales of scoring balloons doubling compared to the previous year[39] - Revenue from the US market increased by 4.3 million (61.6%), primarily due to higher sales of Scoreflex NC and Jade OTW products[48] - Revenue from the Asia-Pacific region increased by 3.5million(23.43.5 million (23.4%), driven by higher sales of coronary and peripheral balloon products in markets like Singapore and Malaysia[48] - Revenue from Japan increased by 2.5 million (14.4%), mainly due to higher sales of Scoreflex TRIO products[48] Product Sales - PCI balloon sales grew by 16.4% to 60.4million,whilePTAballoonsalessurgedby38.560.4 million, while PTA balloon sales surged by 38.5% to 7.7 million in H1 2023[32] - Total sales volume increased by 20.8% to approximately 725,000 units in H1 2023[32] Government Grants - Government grants increased significantly to 1.27millioninH12023,comparedto1.27 million in H1 2023, compared to 0.32 million in H1 2022[18] Tax Rate - The effective tax rate decreased from 17.1% to 10.2% due to the utilization of prior-year tax losses and increased tax-exempt bank interest income[59] Cash and Bank Balances - Cash and bank balances increased to 239.0millionasofJune30,2023,upfrom239.0 million as of June 30, 2023, up from 229.1 million as of December 31, 2022, driven by net operating cash inflows of 12.4millionduringthereportingperiod[62]CurrentRatio−Thecurrentratioimprovedto15.0xasofJune30,2023,upfrom13.2xasofDecember31,2022[63]CapitalExpenditures−Capitalexpenditurestotaled12.4 million during the reporting period[62] Current Ratio - The current ratio improved to 15.0x as of June 30, 2023, up from 13.2x as of December 31, 2022[63] Capital Expenditures - Capital expenditures totaled 4.3 million during the reporting period, primarily for property, plant, equipment, intangible assets, and right-of-use assets[65] Commodity-Linked Fixed-Rate Notes - The company holds commodity-linked fixed-rate notes with a fair value of 19.5million,representing5.219.5 million, representing 5.2% of total assets as of June 30, 2023[65] Employee Count - The company employed 954 full-time employees as of June 30, 2023, with 693 based in China, 108 in Japan, and 66 in European countries[66] Net Proceeds Allocation - Net proceeds from the global offering amounted to approximately HK366.0 million after deducting underwriting commissions, discretionary incentives, and expenses[67] - Net proceeds of HKD 366 million were allocated for various purposes, with 17.1% (HKD 62.7 million) for drug-eluting balloon product development, 4.3% (HKD 15.7 million) for COMBO dual-therapy stent product registration, and 40.8% (HKD 149.3 million) for facility construction and renovation[68] - As of June 30, 2023, HKD 14.4 million of the net proceeds had been utilized, with HKD 351.6 million remaining unused, expected to be utilized by the end of 2027 for various projects[68] - The company plans to acquire a new land plot of approximately 20,000 square meters, with HKD 16.1 million allocated, of which HKD 11.5 million has been utilized as of June 30, 2023[68] - HKD 39.5 million (10.8% of net proceeds) is allocated for potential strategic acquisitions, partnerships, and business development to expand product portfolios and market penetration[68] Dividends - No interim dividend was recommended for the six months ended June 30, 2023, but the board will consider a final dividend to share results with shareholders[69] - The company will consider distributing a final dividend to shareholders, reflecting its strong financial position and positive operating cash flow[46] Share Options - The company granted 6,172,000 share options to employees on July 10, 2023, with an exercise price of HKD 9 and a vesting period from 2024 to 2027[72] Corporate Governance - The Audit Committee reviewed the interim financial statements and confirmed compliance with applicable accounting standards and regulations[73] - The company maintains strong corporate governance, with a board consisting of four executive directors, two non-executive directors, and three independent non-executive directors[70] Subsidiaries and Joint Ventures - OrbusNeich P+F Company Limited is a joint venture in which the company indirectly holds a 50% equity stake[77] - ONM Group Ltd is a wholly-owned subsidiary of the company, registered in the Cayman Islands[78] Reporting Period - The reporting period refers to the six-month period from January 1, 2023 to June 30, 2023[79] Share Incentive Plans - The company adopted Share Incentive Plan A on March 8, 2023 and Share Incentive Plan B on May 16, 2023[79] - The company's equity incentive plans include pre-IPO share option plan, post-IPO share option plan, Share Incentive Plan A and Share Incentive Plan B[79] Research and Development - The company is engaged in research and development of minimally invasive procedures such as TAVR, TMVR, TPVR and TTVR[79] Board of Directors - The company's board of directors includes executive directors Qian Yongxun, Liu Guizhen, Chen Yongcheng and Zhou Jingzhong[80] - The company's non-executive directors include Dr. Zhou Yi and Mr. Liang Dingxin[80] - The company's independent non-executive directors include Chen Yeqiang, Lou Jiaqiang and Dr. Tan Lifen[80] Accounting Standards - The company adopted new accounting standards and amendments, including HKAS 12 (Amendments) related to deferred taxes, effective from January 1, 2023[12] Production Capacity - The new production base in Shenzhen is expected to increase annual production capacity to 1.8 million balloon products and 60,000 stent products[42] - The company plans to build a new R&D and production facility in Hangzhou, which is expected to add an annual production capacity of 2.4 million products[42] Market Strategy - The company plans to promote non-volume-based procurement products in the Chinese market, focusing on microcatheters and peripheral products[45] - The company is actively seeking M&A targets for innovative and high-quality endovascular intervention products to synergize with its extensive sales network[46] Patents and Certifications - The company has over 210 authorized patents and patent applications globally, with more than 30 in the US and 55 in China[40] - The company obtained CE certification for Scoreflex TRIO balloon dilatation catheter and completed CE certification updates for Sapphire PTCA series products under MDR[40]